Hrayr Basmajian
Orthopaedic Trauma · Pomona, CANPI 1982854626
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $74,545 of the $117,985 with a category attached, or 63.2%. Stryker accounts for 64.8% of it on its own, with 23 other manufacturers making up the rest.
Across 288 payments — averaging $409.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$76K
- Acumed LLC$17K
- Smith+Nephew$10K
- US Implant Solutions, LLC$9K
- Synthes USA Products LLC$2K
- Zimmer Biomet$1K
- plus $3K from 18 others
What the payments were for
- Consulting fees$74,54563%
- Speaking & faculty fees$24,46321%
- Travel & lodging$9,0628%
- Food & beverage$9,1708%
- Education$7461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker(2 entities) | 205 | $76,500 |
| Acumed LLC | 21 | $17,111 |
| Smith+Nephew | 10 | $10,055 |
| US Implant Solutions, LLC | 11 | $8,757 |
| Synthes USA Products LLC | 1 | $1,755 |
| Zimmer Biomet | 11 | $1,280 |
| Medical Device Business Services, Inc. | 1 | $1,170 |
| Illuminoss Medical, Inc. | 6 | $215 |
| Curvafix, Inc. | 1 | $197 |
| Davol Inc. | 2 | $181 |
| Globus Medical | 3 | $175 |
| Bone Support Inc. | 1 | $132 |
| Solventum Corporation | 3 | $97 |
| Endeavor Orthopaedics LLC | 1 | $63 |
| Baxter Healthcare | 1 | $44 |
| Baudax Bio Inc. | 1 | $44 |
| Fidia Pharma USA Inc. | 2 | $41 |
| Si-bone, Inc. | 1 | $37 |
| Next Science LLC | 1 | $34 |
| Trice Medical, Inc. | 1 | $30 |
| Empire Medical, Inc | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| ERMI LLC | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VARIAX$32,976
- AXSOS$32,625
- T2 ALPHA$28,906
- HOFFMANN$17,117
- T2$13,403
- Peri-Loc$9,563
- Peri-Loc VLP$9,563
- TRIGEN InterTAN$9,563
- TRIGEN Meta-Nail$9,563
- TRIGEN Sureshot$9,563
- PANGEA$9,000
- PRO$7,203
- ACUMED$7,076
- GAMMA$6,999
- Clavicle Plating System$6,554
- Scapula Plating System$5,800
- EVOLVE$4,275
- EVOLVE TRIAD$4,275
- EVOLVE PROLINE$4,275
- RibLoc$4,000
How this compares
$117,985 in reported general payments places this provider in the 80th percentile of 106 orthopaedic trauma providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 31 | $268 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $189 |
| Ondansetron Hcl | 26 | $81 |
| Meloxicam | 61 | $61 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic trauma in Pomona
- Ryan MayerPomona$27K
- Christopher HayesPomona$22K
- Michael GardnerStanford$2.9M
- Aaron OsborneRedding$1.3M
- Robert Tonksla Jolla$1.3M
- John ScolaroOrange$1M
- David LowenbergSan Francisco$788K
- Eric LindvallClovis$609K
- Christopher LeeLos Angeles$475K
- Joshua GaryLos Angeles$466K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.